

1 **Early emergence phase of SARS-CoV-2 Delta variant in Florida**

2 Eleonora Cella¹, Sobur Ali¹, Sarah E. Schmedes², Brittany Rife^{3,4}, Simone Marini⁵, Marco
3 Salemi^{3,4}, Jason Blanton², Taj Azarian^{1*}

4
5 ¹Burnett School of Biomedical Sciences, University of Central Florida, Orlando, FL

6 ²Bureau of Public Health Laboratories, Florida Department of Health, Jacksonville, FL

7 ³Emerging Pathogens Institute, University of Florida, Gainesville, FL

8 ⁴Department of Pathology, Immunology, and Laboratory Medicine, University of Florida,
9 Gainesville, FL

10 ⁵Department of Epidemiology, University of Florida, Gainesville, FL

11

12 *** Correspondence and requests for materials should be addressed to:** taj.azarian@ucf.edu

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32 **Abstract**

33 SARS-CoV-2, the causative agent of COVID-19, emerged in late 2020. The highly contagious
34 B.1.617.2 (Delta) Variant of Concern (VOC) was first identified in October 2020 in India and
35 subsequently disseminated worldwide, later becoming the dominant lineage in the U.S. Despite
36 considerable genomic analysis of SARS-CoV-2 in the U.S., several gaps in the understanding of
37 the local dynamics during early introductions remain, which when elucidated could translate the
38 results of viral genomic epidemiology to actionable mitigation efforts. Here, we explore the early
39 emergence of the Delta variant in Florida, U.S. using phylogenetic analysis of representative
40 Florida and globally sampled genomes. We find multiple independent introductions into Florida
41 primarily from North America and Europe, with a minority originating from Asia. These
42 introductions lead to three distinct clades that demonstrated varying relative rates of transmission
43 and possessed five distinct substitutions that were 3-21 times more prevalent in the Florida sample
44 as compared to the global sample. Our results underscore the benefits of routine viral genomic
45 surveillance to monitor epidemic spread and support the need for more comprehensive genomic
46 epidemiology studies of emerging variants. In addition, we provide a model of epidemic spread of
47 newly emerging VOCs that can inform future public health responses.

48 **Keywords:** SARS-CoV-2; Delta; early emergence; Florida; Phylogenetic analysis.

49

50

51

52

53

54

55

56 **Introduction**

57 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the causative agent of
58 COVID-19 disease, emerged in Wuhan city, China at the end of 2019 [1]. The virus subsequently
59 spread globally, resulting in over 260 million infections and five million deaths. This global
60 account included more than 45 million cases in the United States (U.S.) as of November 30th, 2021.
61 Several SARS-CoV-2 variants have since emerged globally through continuous viral genome
62 evolution [2]. The emergence of novel SARS-CoV-2 variants of concern (VOC) with increased
63 infectivity, transmissibility, and/or virulence potential as compared to their progenitor lineage
64 poses serious public health concerns. In particular, it is difficult to predict how VOCs will affect
65 pandemic dynamics in the context of varying population immunity. Most concerning are VOCs
66 that evade vaccine-induced immunity due to immune pressure[3].

67 Emergence of VOCs in the U.S. began in the fall of 2020 [4,5]. The SARS-CoV-2 Delta
68 variant (B.1.617.2) was first identified in India in October, 2020 and became the dominant variant
69 with a ferocious wave of infection in April-May of 2021. After April, 2021, the variant had spread
70 in and among 65 countries across six continents globally [6] and was designated as a VOC by the
71 U.S. Centers for Disease Control and Prevention (CDC)[7] and World Health Organization
72 (WHO)[8] on May, 2021. In the United Kingdom (UK), the variant spread rapidly due to travel
73 importation followed by community transmission and became the dominant variant responsible
74 for 90% of the cases by June, 2021, overtaking the previously predominant Alpha variant (B.1.1.7)
75 [9] [10]. In the U.S., the Delta variant was first detected by mid-March, 2021, and rapidly led to a
76 new wave of infection in many locations. A nationwide study in the U.S. reported a drop of Alpha
77 variant cases from 70% in late April to 42% in mid-June, with the B.1.617.2 variant leading much
78 of the shift [11]. Beginning in the summer of 2021, Delta became the predominant lineage in North
79 America, as well as in South Africa, India, UK and Canada [10,12–15].

80 Compared to its predecessor Alpha, the Delta variant possesses 12 notable mutations in the
81 genomic region encoding the spike protein that provide a fitness advantage. In particular, the
82 D614G substitution, which is shared with other VOCs including Alpha, Beta, Gamma and the
83 more recently emerging Omicron, has been associated with increased transmissibility, infectivity,
84 and severity relative to the original circulating strains [13,16–20], and experimental studies
85 showed reduced neutralization of B.1.617.2 by vaccine/convalescent sera [21,22]. Multiple
86 observational studies also reported on the reduced efficacy of the COVID-19 vaccines [19,23,24],

87 higher replication efficiency with an average doubling time of 25 days [25], and increased attack
88 rate among younger, unvaccinated age groups [26]. The prevalence of Delta variants in
89 unvaccinated individuals was three times that in fully vaccinated individuals in the UK, and social
90 mixing had the potential to increase in infections, even with high levels of vaccination [26]. A
91 recent study in South Korea indicated that pre-symptomatic transmission, superspreading
92 potential, and the higher transmissibility of the Delta variant likely contributed to the secondary
93 infection rate [27].

94 Florida is the 3rd most populous state in the U.S., a popular tourist destination, and a conduit
95 to the rest of the country through its 26 major airports and eight major ports. Historically, Florida
96 has been the epicenter of notable public health events and responses such as the emergence of Zika
97 Virus in 2016 [28]. As such, the dynamics of introduction, spread, and exportation are important
98 for the region. These dynamics are of particular importance since the emergence and subsequent
99 spread of Delta varied considerably across geographic locations based on host demographic
100 structure, circulating variants, historical incidence, and vaccination rates[29–31]. At the time Delta
101 was introduced to Florida, there were no enforced statewide travel restrictions or mask
102 requirements, schools were conducted in-person, and vaccination was limited to individuals over
103 40 years of age or in target risk groups. Here, we sought to investigate the early emergence of
104 Delta in Florida during a period with high background circulation of another variant (Alpha) by
105 analyzing SARS-CoV-2 viral genome sequence data from Florida in the context of global data.
106 Our findings provide insight into the introduction dynamics of future SARS-CoV-2 variants.

107

108 **Materials and Methods**

109 *Dataset*

110 All available genomes assigned as Delta were downloaded, excluding the low coverage
111 and incomplete records, from GISAID (www.gisaid.org) as of July 13th, 2021. Subsampling was
112 performed to reduce the dataset for feasible computational analysis. A subsampling strategy was
113 chosen to minimize the unbalanced representation of location-specific data while maximizing the
114 genetic diversity and temporal distribution of sampling times for each geographic location using
115 the Temporal And diveRsity Distribution Sampler for Phylogenetics (TARDiS) [32]. Each
116 country was considered a distinct geographic location, with Florida considered distinct from the

117 remainder of the United States. Subsampling 213 genomic sequences from each of these 18
118 locations resulted in 5,500 total sequences.

119 Viral genome sequences were aligned using ViralMSA with default parameters [33] using
120 Wuhan-1 (MN908947.3) as reference. Manual curation using Aliview was performed to specify
121 start site and remove artifacts at the terminal regions [34]. Maximum likelihood (ML) tree
122 reconstruction using IQTREE (version 1.6.10) was employed, using the best-fit model of
123 nucleotide substitution according to the Bayesian Information Criterion (BIC) as indicated by the
124 Model Finder function [35]. The statistical robustness of individual nodes was determined using
125 1,000 bootstrap replicates. The final dataset comprised 5,500 complete or near-complete SARS-
126 CoV-2 genome sequences.

127

128 *Phylogenetic Analysis*

129 We then sought to estimate the change in virus effective population size (N_e) over time and
130 dynamic aspects of population structure in the context of Florida transmission. The ML tree was
131 first assessed for the presence of temporal signal by evaluating the linear relationship between
132 genetic distance of each tip from the best-fitting root of the tree (rooted on the branch that
133 minimizes the mean square of the residuals) with its respective sampling time using TempEst
134 v1.5.3 [36]. Temporal signal was evidenced by a positive relationship, allowing for subsequent
135 dating of internal nodes via molecular clock calibration of tree tips using the *treedater* package in
136 R v3.6.0 [37,38]. A constant evolutionary rate of 8.0×10^{-4} nucleotide substitutions per site per
137 year [12,39] was used to re-scale branch lengths (substitutions/site) of the ML tree in units of time
138 within TimeTree [40]. To estimate an upper limit of the number of and source of viral introductions
139 into Florida, we then fit a migration model in TreeTime for which geographical locations were
140 assigned to external (known based on sampling location) and internal nodes (inferred) [40]. Using
141 the resulting annotated tree topology, we quantified transitions between internal nodes assigned to
142 Florida and the other geographic locations included in the dataset, which represented putative
143 importations and exportations.

144 The population structure of Florida Delta genomes was assessed to determine dominant
145 sub-lineages indicative of distinct epidemic foci. Focused Bayesian molecular clock analysis was
146 then conducted on the resulting individual clades using BEAST 1.10.4 [41]. Simultaneous
147 molecular clock calibration and coalescent N_e estimation was modeled using a strict molecular

148 clock (constant evolutionary rate), HKY model of nucleotide substitution [42], and exponential
149 growth in population size [43]. We computed Markov chain Monte Carlo (MCMC) triplicate runs
150 of 100 million states each, sampling every 10,000 steps for each data set. Tracer v.1.7.1 was used
151 to evaluate effective sampling sizes for relevant parameters, using 200 as the minimum threshold
152 for sufficient MCMC sampling [44]. Maximum clade credibility trees were summarized from the
153 MCMC samples using TreeAnnotator after discarding 10% as burn-in.

154 Last, we assessed variation in relative transmission dynamics among individual clades as
155 well as local Florida sub-trees within each clade in the context of mutational patterns. For each
156 cluster, we calculated the *Oster* statistic, which is a function of the size in tips, the sum of the
157 branch lengths, and the length of the longest branch within an individual subtree [45,46]. This
158 method was recently developed to infer transmission rates using human immunodeficiency virus
159 (HIV) sequencing data.

160

161

162

163

164


165

166

167 **Results**

168 By July 2021, 2.4 million COVID-19 cases were reported in Florida and an estimated 11.3
169 million people had received at least one dose of the vaccine. A significant reduction in the number
170 of infections in Florida was observed at the beginning of 2021, during a period that was dominated
171 by the Alpha variant (B.1.1.7, Figure 1A). After a period of seemingly stable epidemic recession,
172 with few new cases detected between February – June 2021, a new epidemic wave impacted the
173 state, resulting in a significant increase in incidence. This wave coincides with the introduction of
174 the Delta variant to the state, increasing from 28.7% to 54.3% of genomes submitted to GISAID
175 (July 13th, 2021, Figure 1 A). Within 3 months of its introduction, the Delta variant had completely
176 supplanted Alpha as the most prevalent variant, accounting for 7.5% of all Florida sequenced
177 genomes. When the Delta wave began in March 2021, vaccination was limited to healthcare
178 professionals, individuals >40 years of age, and persons at high risk for severe disease (e.g.,
179 immune-compromised). As a result, only 28% of the Florida population had received one vaccine
180 dose and ~10% were fully vaccinated (Figure 1B). On April 5, vaccine eligibility was extend to
181 individuals >18 years of age [47] and the Food & Drug Administration approved the Pfizer
182 COVID-19 vaccine for individuals 12 years of age or older on May 12th (Figure 1) [48].

183




184

185 **Figure 1. Infection distribution over time in the context of SARS-CoV-2 lineages and vaccination.** A: Distribution (y-axes) of
 186 previously considered variants of concern (VOC) over time (x-axis) in terms of number of weekly confirmed cases (top), count of
 187 sequenced isolates stratified by VOC (middle), and the proportion of VOC (bottom). Remaining lineages are grouped into “Other”.
 188 B: Vaccinated individuals (defined as *incomplete* for a single dose of Moderna or Pfizer and *fully* for two doses of Moderna or
 189 Pfizer and a single dose of Johnson&Johnson, top) and cumulative number of weekly confirmed cases (bottom) over time (x-axis).

190

191 Analysis of 5,500 publicly available genomes (446 Florida genomes with a representative
 192 subset of 5,054 genomes sampled globally) showed that Florida samples possessed characteristic
 193 Delta substitutions in the region encoding the spike protein except for a E156G substitution, which
 194 was not found among early Florida genomes (Figure 2). Five, less common substitutions emerged
 195 among Delta variants from Florida, including K77T, A222V, V289I, and V1264L, which were 3-
 196 21 times more prevalent in the Florida sample as compared to the global sample. In addition, T95I,
 197 common also among Iota and Mu variants, was found to be at a lower prevalence than the global
 198 sample (8.5% instead of 22.1%).


199



200
 201 **Figure 2. Distribution of Spike protein substitutions among Florida SARS-CoV-2 Delta (B.1.617.2) variant genomes.** The x-
 202 axis shows the coordinates of the region encoding the spike protein with its regions and the y-axis shows the proportion of genomes
 203 carrying the substitution. The substitutions with a prevalence greater than 2% are annotated. The inlaid table includes the Delta
 204 variant characterizing substitutions in spike protein region, the prevalence among Florida genomes, and the prevalence among
 205 worldwide Delta genomes sampled from GISAID (*) ([https://outbreak.info/compare-](https://outbreak.info/compare-lineages?pango=B.1.617.2&gene=S&threshold=0.2)
 206 [lineages?pango=B.1.617.2&gene=S&threshold=0.2](https://outbreak.info/compare-lineages?pango=B.1.617.2&gene=S&threshold=0.2)).

207
 208 Linear regression of root-to-tip genetic distances against sampling dates indicated that the
 209 SARS-CoV-2 sequences evolve in a clock-like manner ($r = 0.30$) (Supplementary Figure 1).

210




211

212 **Supplementary figure 1. Analysis of temporal structure.** Root-to-tip genetic divergence for the whole dataset against
213 time of sampling.

214

215 Ancestral location reconstruction of the time-scaled tree elucidated the number and timing
216 of viral migrations between Florida and the rest of the world (Figure 3). A total of 88 transitions
217 from internal nodes assigned to allopatric locations to those assigned to Florida were observed in
218 the phylogeny. Multiple inferred introductions to Florida occurred in late March to early April
219 2021 from India, followed by onward migration to the U.S. starting in May (Figure 3A).
220 Subsequent inferred introductions from other geographical locations were observed during the end
221 of June 2021 as the Delta epidemic expanded. Overall, the greatest number of introduction events
222 to Florida were observed to originate from the U.S., followed by Europe (lines marked in black,
223 Figure 3B). Taxa from Florida were also intermediate in transitions between allopatric locations
224 and the remaining U.S., accounting for nearly two-thirds of the number of migration events (double
225 the number of inferred introductions into Florida, Figure 3B).

226



227
228 **Figure 3. Sources of viral exchanges (imports and exports) in and outside Florida.** Movement was inferred using ancestral
229 reconstruction of geographic states within the phylogenetic tree of genomic samples. **A.** Total number of viral introductions over
230 time into Florida. **B.** Graphical representation of the estimated number of migration events between the geographic areas;
231 introductions into the state of Florida are outlined in black.

232
233

234 Independent concurrent migrations of Delta to Florida from North America, Europe, and
235 Asia, occurring as early as April 2021, can be visualized on the ML time-tree (Figure 4). Based
236 on internal support for divergence events within the tree (bootstrap values > 0.70), three distinct
237 clades were identified: Subset I (n = 1026) comprised of 188 FL genomes; Subset II (n = 327)
238 comprised 101 FL genomes, and Subset III (n = 470) comprised 83 FL genomes (Figure 4A, clade
239 highlighted in grey and marked as I-III). These well-supported clades represent distinct foci of the
240 local epidemic seeded by multiple introductions.

241 To assess these clades in more detail, we performed a separate Bayesian coalescent analysis
242 (Figure 4B-D). The maximum clade credibility (MCC) trees showed four subtrees comprised
243 predominately of Florida taxa, representing local spread (Figure 4B-D); all Florida subtrees
244 presented with similar upper estimates of the timing of introduction - April 2021 (Figure 4B-D).
245 However, the Florida clusters in panel C and D have very low statistical support due to the low
246 genetic diversity of SARS-CoV-2 genomes sampled within a short time period [49–52]. When
247 assessing clade-defining substitutions, we identified that spike A222V and V289I were isolated to
248 Subset I genomes and K77T associated with Subset II. Further, a subclade of Subset I possessed
249 both A222V and V289I, while another only carried A222V.

250 Comparison of transmission dynamics of each three clades and their respective subtrees
251 found that Subset II exhibited the highest relative rate of transmission, followed by Subset III, then

252 Subset I; however, there was no clear association between the above-described mutations and
253 relative transmission rates. Further, there was no significant difference in geographic composition
254 of each clade when assessed in context of transmission rates (Figure 4). Florida subtrees exhibited
255 a broader range of estimated transmission rates (0.62 vs. 0.14 units), which were generally higher
256 than the background Subsets (Table 1), except for Florida Subtree C and its Subset II. Florida
257 Subtree D showed evidence of the highest relative rate of transmission (2.13 units) as compared
258 to its progenitor clade, Subtree III.

259

260 **Table 1.** Subset/subtree statistics (number of taxa, percentage of FL taxa, minor mutations
261 associated and absolute Oster value).

<i>Subset/ Subtree</i>	<i>N of taxa</i>	<i>% of FL taxa</i>	<i>Minor mutations associated</i>	<i>Oster value</i>
Subset I	1026	18.3%	A222V, V289I	1.31
<i>Subtree B1</i>	74	95.9%	A222V	1.59
<i>Subtree B2</i>	88	100.0%	A222V, V289I	1.83
Subset II	326	30.7%	K77T	1.52
<i>Subtree C</i>	91	98.9%	K77T	1.51
Subset III	470	17.7%	-	1.45
<i>Subtree D</i>	22	81.8%	-	2.14


262

263

264

265

266



267

268 **Figure 4.** Time-resolved Maximum Likelihood trees containing high-quality Delta SARS-CoV-2 near-full-genome sequences. **A.**

269 Full time-resolved Maximum Likelihood tree for all sequence data. The three clades identified as being well-supported using

270 bootstrap (BS) analysis (BS>70) are highlighted in grey (referred to as clades I-III). A pie chart indicating the location distribution

271 is located on top of each of the three clades. **B-D.** MCC tree reconstruction for the three clades (I-III) individually. Tree tips are

272 colored according to their location (continent) and the color legend is on the top right of the figure.

273

274 **Discussion**

275 Genomic epidemiology has been integral in understanding SARS-CoV-2 emergence and
276 spread and for tracking the evolutionary dynamics of viral transmission. In view of this, we
277 investigated the introduction of the SARS-CoV-2 Delta variant in Florida, U.S. from the early
278 identification and the main peak of infection that occurred in July 2021. By June 2021, the Delta
279 variant had become the dominant lineage in the US, unseating the Alpha variant as the most
280 prevalent lineage in Florida, U.S., and abroad [12,14]. Subsequently, Delta received considerable
281 attention due to its rapid dispersal, high transmission rate, and association with vaccine failure
282 through vaccine breakthrough cases [15].

283 These findings provide insight into the introduction and emergence of a novel SARS-CoV-
284 2 variant (Delta) to a region with moderate population-level immunity and ongoing transmission
285 of a resident variant (Alpha). The introduction of Delta variant to Florida was observed in early
286 and late April 2021 primarily from India, which is consistent with the previously reported origins
287 [12]. Multiple international introductions were observed at the end of June 2021 when about 45%
288 of the state's eligible population was fully vaccinated, and about 53% had received at least one
289 dose of vaccine in Florida [53].

290 Early Florida Delta isolates were interspersed among the isolates from other countries in
291 the phylogeny, suggesting multiple introductions with most dating to early April 2021. These
292 introductions coalesced into three distinct clades that dominated the early period of the Delta wave
293 and resulted in the near complete replacement of the resident Alpha variant. A similar dynamic of
294 multiple repeated introduction followed by rapid interstate transmission was observed in the U.S.
295 after introduction of the Alpha variant [54,55]. While international and domestic travel was muted
296 at the time Delta was introduced to Florida, there were no explicit restrictions. Likewise, as Delta
297 completely displaced Alpha, Omicron could potentially displace Delta worldwide [56]; however,
298 several scenarios could be considered, such as a long-term co-circulation or an Omicron wave
299 followed by resurgence of Delta. The outcome of these scenarios may be affected by the
300 combination of immune escape and intrinsic transmissibility. This will influence the endemic state
301 of the virus, public health response, and changes to vaccination rates or other social practices. Last,
302 as evidenced by our analysis of relative rates of transmission, there was considerable variation in
303 transmission dynamics of dominant Florida Delta clades independent of mutational profile or

304 geographic composition of the progenitor lineages that seeded the local epidemic. This points to
305 differences in host factors or public health measures that warrant further investigation.

306 As vaccine coverage rates remain low globally, the continued emergence of variants of
307 concern remains likely, thus emphasizing the need for targeted viral genomic surveillance and
308 expansion of novel surveillance tools. Two promising approaches are the use of wastewater
309 surveillance at both the municipality level and targeted settings (e.g., airports) as well as the
310 application of air collection monitors to detect SARS-CoV-2 in the environment (DH O'Connor,
311 2022, In Preparation). When deployed, these tools can be used to assess the risk of infection in a
312 setting, detect the emergence of novel variants, and track viral diversity and coupled with expanded
313 viral genomic surveillance of COVID-19 cases create a robust network for situational awareness
314 of the evolving pandemic.

315 Although the sequence data alone do not represent the true number of epidemiologically
316 linked transmission chains, our phylogenetic findings clearly elucidate multiple introductions of a
317 novel variant to a population with moderate levels of population immunity, a prevailing resident
318 variant, and the absence of mandates. When interpreting our results, it's worth noting that
319 importations and exportations were inferred from available sequence data available in GISAID.
320 The availability of these data is influenced by several factors including SARS-CoV-2 testing and
321 genomic surveillance capacity among countries. Further, whereas increased rates for Florida
322 subtrees likely reflect local transmission dynamics, additional case-level data is required for more
323 resolved investigation into the relative contribution of host and pathogen factors associated with
324 differences. Nonetheless, our results further underscore the benefits of routine pathogen genomic
325 surveillance to monitor outbreak investigations and support the need for more comprehensive
326 epidemiological studies of newly emerging variants. They also provide a likely scenario for the
327 trajectory of Omicron and subsequent variants whether emerging domestically or imported,
328 reinforcing the necessity of continued genomic surveillance efforts globally.

329

330

331

332

333

334

335 **Author Contributions:** Conceptualization, MS and TA; Analysed the data: EC, BR, SM;
336 Helped with study design and data interpretation: EC, SA, and TA; Writing – Original Draft
337 Preparation, EC, SA, BR. Writing – Review & Editing, SES, MS, JB, TA. Supervision, MS, TA.

338
339 **Funding:** This work was funded in part by a grant from The Rockefeller Foundation to the
340 University of Florida and the University of Central Florida in order to accelerate regional genomic
341 surveillance. The views and findings are those of the author and not those of the funder (The
342 Rockefeller Foundation). This work was funded in part by Epidemiology and Laboratory Capacity
343 award from the CDC Office of Advanced Molecular Detection to the Florida Department of Health
344 Bureau of Public Health Laboratories.

345
346 **Institutional Review Board Statement:** Not applicable

347 **Informed Consent Statement:** Not applicable.

348 **Data Availability Statement:** All input files along with all resulting output files and scripts used
349 in the present study will be made available upon request.

350
351 **Acknowledgments:** We thank the global laboratories that generated and made public the SARS-
352 CoV-2 sequences (through GISAID) used as reference dataset in this study (Supplementary table
353 1).

354 **Conflicts of Interest:** The authors declare no conflict of interest.

355

356 References

- 357 1. Wu, F.; Zhao, S.; Yu, B.; Chen, Y.-M.; Wang, W.; Song, Z.-G.; Hu, Y.; Tao, Z.-W.; Tian,
358 J.-H.; Pei, Y.-Y.; et al. A new coronavirus associated with human respiratory disease in
359 China. *Nature* **2020**, *579*, 265–269, doi:10.1038/s41586-020-2008-3.
- 360 2. Abdool Karim, S.S.; de Oliveira, T. New SARS-CoV-2 Variants — Clinical, Public
361 Health, and Vaccine Implications. *N. Engl. J. Med.* **2021**, *384*, 1866–1868,
362 doi:10.1056/nejmc2100362.
- 363 3. Thye, A.Y.K.; Law, J.W.F.; Pusparajah, P.; Letchumanan, V.; Chan, K.G.; Lee, L.H.
364 Emerging sars-cov-2 variants of concern (Vocs): An impending global crisis.
365 *Biomedicines* **2021**, *9*.
- 366 4. Hou, Y.J.; Chiba, S.; Halfmann, P.; Ehre, C.; Kuroda, M.; Dinnon, K.H.; Leist, S.R.;
367 Schäfer, A.; Nakajima, N.; Takahashi, K.; et al. SARS-CoV-2 D614G variant exhibits
368 efficient replication ex vivo and transmission in vivo. *Science (80-.)*. **2020**, *370*, 1464–
369 1468, doi:10.1126/science.abe8499.
- 370 5. Yurkovetskiy, L.; Wang, X.; Pascal, K.E.; Tomkins-Tinch, C.; Nyalile, T.P.; Wang, Y.;
371 Baum, A.; Diehl, W.E.; Dauphin, A.; Carbone, C.; et al. Structural and Functional
372 Analysis of the D614G SARS-CoV-2 Spike Protein Variant. *Cell* **2020**, *183*, 739-751.e8,
373 doi:10.1016/j.cell.2020.09.032.
- 374 6. Elbe, S.; Buckland-Merrett, G. Data, disease and diplomacy: GISAID’s innovative
375 contribution to global health. *Glob. Challenges* **2017**, *1*, 33–46, doi:10.1002/gch2.1018.
- 376 7. CDC SARS-CoV-2 Variant Classifications and Definitions. *Cdc* **2021**, 1–12.
- 377 8. World Health Organization Tracking SARS-CoV-2 variants. *Who* **2021**,
378 <https://www.who.int/en/activities/tracking-SARS-Co>.
- 379 9. Robishaw, J.D.; Alter, S.M.; Solano, J.J.; Shih, R.D.; DeMets, D.L.; Maki, D.G.;
380 Hennekens, C.H. Genomic surveillance to combat COVID-19: challenges and
381 opportunities. *The Lancet Microbe* **2021**, *2*, e481–e484, doi:10.1016/s2666-
382 5247(21)00121-x.
- 383 10. Torjesen, I. Covid-19: Delta variant is now UK’s most dominant strain and spreading
384 through schools. *BMJ* **2021**, *373*, n1445, doi:10.1136/bmj.n1445.
- 385 11. Bolze, A.; Cirulli, E.T.; Luo, S.; White, S.; Cassens, T.; Jacobs, S.; Nguyen, J.; Ramirez,
386 J.M.; Sandoval, E.; Wang, X. Rapid displacement of SARS-CoV-2 variant B. 1.1. 7 by B.

- 387 1.617. 2 and P. 1 in the United States. *medRxiv* **2021**, 2021.06.20.21259195,
388 doi:10.1101/2021.06.20.21259195.
- 389 12. Tegally, H.; Wilkinson, E.; Althaus, C.L.; Giovanetti, M.; San, J.E.; Giandhari, J.; Pillay,
390 S.; Naidoo, Y.; Ramphal, U.; Msomi, N.; et al. Rapid replacement of the Beta variant by
391 the Delta variant in South Africa. *medRxiv* **2021**, 2021.09.23.21264018,
392 doi:10.1101/2021.09.23.21264018.
- 393 13. Sheikh, A.; McMenamin, J.; Taylor, B.; Robertson, C. SARS-CoV-2 Delta VOC in
394 Scotland: demographics, risk of hospital admission, and vaccine effectiveness. *Lancet*
395 **2021**, *397*, 2461–2462.
- 396 14. Bolze, A.; Luo, S.; White, S.; Cirulli, E.T.; Wyman, D.; Dei Rossi, A.; Machado, H.;
397 Cassens, T.; Jacobs, S.; Schiabor Barrett, K.M.; et al. SARS-CoV-2 Variant Delta Rapidly
398 Displaced Variant Alpha in the United States and Led to Higher Viral Loads. *SSRN*
399 *Electron. J.* **2021**, 2021.06.20.21259195, doi:10.2139/ssrn.3952083.
- 400 15. U.S. CDC Delta Variant: What We Know About the Science | CDC Available online:
401 <https://www.cdc.gov/coronavirus/2019-ncov/variants/delta-variant.html> (accessed on Nov
402 5, 2021).
- 403 16. Korber, B.; Fischer, W.M.; Gnanakaran, S.; Yoon, H.; Theiler, J.; Abfalterer, W.;
404 Hengartner, N.; Giorgi, E.E.; Bhattacharya, T.; Foley, B.; et al. Tracking Changes in
405 SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus.
406 *Cell* **2020**, *182*, 812-827.e19, doi:10.1016/j.cell.2020.06.043.
- 407 17. Volz, E.; Hill, V.; McCrone, J.T.; Price, A.; Jorgensen, D.; O’Toole, Á.; Southgate, J.;
408 Johnson, R.; Jackson, B.; Nascimento, F.F.; et al. Evaluating the effects of SARS-CoV-2
409 Spike mutation D614G on transmissibility and pathogenicity. *medRxiv* **2020**, *184*, 64–75,
410 doi:10.1101/2020.07.31.20166082.
- 411 18. Daniloski, Z.; Jordan, T.X.; Ilmain, J.K.; Guo, X.; Bhabha, G.; Tenoever, B.R.; Sanjana,
412 N.E. The spike d614g mutation increases sars-cov-2 infection of multiple human cell
413 types. *Elife* **2021**, *10*, 1–16, doi:10.7554/eLife.65365.
- 414 19. Deng, X.; Garcia-Knight, M.A.; Khalid, M.M.; Servellita, V.; Wang, C.; Morris, M.K.;
415 Sotomayor-González, A.; Glasner, D.R.; Reyes, K.R.; Gliwa, A.S.; et al. Transmission,
416 infectivity, and neutralization of a spike L452R SARS-CoV-2 variant. *Cell* **2021**, *184*,
417 3426-3437.e8, doi:10.1016/j.cell.2021.04.025.

- 418 20. Hester Allen, MSc, Amoolya Vusirikala, MFPH, Joe Flannagan, MSc, K.A.; Twohig,
419 MPH, Asad Zaidi, MSc, COG-UK Consortium, Natalie Groves, MSc, J.; Lopez-Bernal,
420 FFPH, Ross Harris, PhD, Andre Charlett, PhD, Gavin Dabrera, F.; Meaghan Kall, M.
421 Increased household transmission of COVID-19 cases associated with SARS-CoV-2
422 Variant of Concern B.1.617.2: a national case-control study.
- 423 21. Liu, C.; Ginn, H.M.; Dejnirattisai, W.; Ren, J.; Stuart, D.I.; Screaton, G.R. Article
424 Reduced neutralization of SARS-CoV-2 B . 1 . 617 by vaccine and convalescent serum
425 Reduced neutralization of SARS-CoV-2 B . 1 . 617 by vaccine and convalescent serum.
426 *Cell* **2021**, *184*, 1–17.
- 427 22. Planas, D.; Veyer, D.; Baidaliuk, A.; Staropoli, I.; Guivel-Benhassine, F.; Rajah, M.M.;
428 Planchais, C.; Porrot, F.; Robillard, N.; Puech, J.; et al. Reduced sensitivity of infectious
429 SARS-CoV-2 variant B.1.617.2 to monoclonal antibodies and sera from convalescent and
430 vaccinated individuals. *bioRxiv* **2021**, 2021.05.26.445838.
- 431 23. Yadav, P.D.; Ph, D.; Sapkal, G.N.; Ph, D.; Ella, R.; Sahay, R.R.; Ph, D. Neutralization
432 against B . 1 . 351 and B . 1 . 617 . 2 with sera of COVID-19 recovered cases and
433 vaccinees of BBV152 Corresponding author * : *bioRxiv* **2021**, 1–10.
- 434 24. Wall, E.C.; Wu, M.; Harvey, R.; Kelly, G.; Warchal, S.; Sawyer, C.; Daniels, R.; Adams,
435 L.; Hobson, P.; Hatipoglu, E.; et al. AZD1222-induced neutralising antibody activity
436 against SARS-CoV-2 Delta VOC. *Lancet* **2021**, *398*, 207–209.
- 437 25. Challen, R.; Dyson, L.; Overton, C.E.; Guzman-Rincon, L.M.; Hill, E.M.; Stage, H.B.;
438 Brooks-Pollock, E.; Pellis, L.; Scarabel, F.; Pascall, D.J.; et al. Early epidemiological
439 signatures of novel SARS-CoV-2 variants: establishment of B.1.617.2 in England.
440 *medRxiv* **2021**, 2021.06.05.21258365, doi:10.1101/2021.06.05.21258365.
- 441 26. Elliott, P.; Haw, D.; Wang, H.; Eales, O.; Walters, C.E.; Ainslie, K.E.C.; Atchison, C.;
442 Fronterre, C.; Diggle, P.J.; Page, A.J.; et al. Exponential growth, high prevalence of
443 SARS-CoV-2, and vaccine effectiveness associated with the Delta variant. *Science* (80-.).
444 *0*, eabl9551, doi:10.1126/science.abl9551.
- 445 27. Hwang, H.; Lim, J.-S.; Song, S.-A.; Achangwa, C.; Sim, W.; Kim, G.; Ryu, S.
446 Transmission Dynamics of the Delta Variant of SARS-CoV-2 Infections in South Korea.
447 *J. Infect. Dis.* **2021**, doi:10.1093/infdis/jiab586.
- 448 28. Likos, A.; Griffin, I.; Bingham, A.M.; Stanek, D.; Fischer, M.; White, S.; Hamilton, J.;

- 449 Eisenstein, L.; Atrubin, D.; Mulay, P.; et al. Local Mosquito-Borne Transmission of Zika
450 Virus — Miami-Dade and Broward Counties, Florida, June–August 2016. *MMWR. Morb.*
451 *Mortal. Wkly. Rep.* **2016**, *65*, 1032–1038, doi:10.15585/mmwr.mm6538e1.
- 452 29. Singanayagam, A.; Hakki, S.; Dunning, J.; Madon, K.J.; Crone, M.A.; Koycheva, A.;
453 Derqui-Fernandez, N.; Barnett, J.L.; Whitfield, M.G.; Varro, R.; et al. Community
454 transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in
455 vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort
456 study. *Lancet Infect. Dis.* **2021**, *0*, doi:10.1016/S1473-3099(21)00648-4.
- 457 30. Mahase, E. Delta variant: What is happening with transmission, hospital admissions, and
458 restrictions? *BMJ* **2021**, *373*, n1513, doi:10.1136/bmj.n1513.
- 459 31. Del Rio, C.; Malani, P.N.; Omer, S.B. Confronting the Delta Variant of SARS-CoV-2,
460 Summer 2021. *JAMA - J. Am. Med. Assoc.* 2021, *326*, 1001–1002.
- 461 32. Marini, S.; Mavian, C.; Riva, A.; Prosperi, M.; Salemi, M.; Rife Magalis, B. Optimizing
462 viral genome subsampling by genetic diversity and temporal distribution (TARDiS) for
463 phylogenetics. *Bioinformatics* **2022**, *38*, 856–860, doi:10.1093/bioinformatics/btab725.
- 464 33. Moshiri, N. ViralMSA: Massively scalable reference-guided multiple sequence alignment
465 of viral genomes. *Bioinformatics* **2021**, *37*, 714–716, doi:10.1093/bioinformatics/btaa743.
- 466 34. Larsson, A. AliView: A fast and lightweight alignment viewer and editor for large
467 datasets. *Bioinformatics* **2014**, *30*, 3276–3278, doi:10.1093/bioinformatics/btu531.
- 468 35. Nguyen, L.T.; Schmidt, H.A.; Von Haeseler, A.; Minh, B.Q. IQ-TREE: A fast and
469 effective stochastic algorithm for estimating maximum-likelihood phylogenies. *Mol. Biol.*
470 *Evol.* **2015**, *32*, 268–274, doi:10.1093/molbev/msu300.
- 471 36. Rambaut, A.; Lam, T.T.; Carvalho, L.M.; Pybus, O.G. Exploring the temporal structure of
472 heterochronous sequences using TempEst (formerly Path-O-Gen). *Virus Evol.* **2016**, *2*,
473 doi:10.1093/ve/vew007.
- 474 37. Volz, E.M.; Frost, S.D.W. Scalable relaxed clock phylogenetic dating. *Virus Evol.* **2017**,
475 *3*, doi:10.1093/ve/vex025.
- 476 38. Team, R. core R: A language and environment for statistical computing Available online:
477 <https://www.r-project.org/>.
- 478 39. Giovanetti, M.; Cella, E.; Benedetti, F.; Magalis, B.R.; Fonseca, V.; Fabris, S.; Campisi,
479 G.; Ciccozzi, A.; Angeletti, S.; Borsetti, A.; et al. SARS-CoV-2 shifting transmission

- 480 dynamics and hidden reservoirs limited the efficacy of public health interventions in Italy.
481 *Commun. Biol.* **2020**, doi:10.1101/2020.12.16.20248355.
- 482 40. Sagulenko, P.; Puller, V.; Neher, R.A. TreeTime: Maximum-likelihood phylodynamic
483 analysis. *Virus Evol.* **2018**, *4*, doi:10.1093/ve/vex042.
- 484 41. Suchard, M.A.; Lemey, P.; Baele, G.; Ayres, D.L.; Drummond, A.J.; Rambaut, A.
485 Bayesian phylogenetic and phylodynamic data integration using BEAST 1.10. *Virus Evol.*
486 **2018**, *4*, doi:10.1093/ve/vey016.
- 487 42. Hasegawa, M.; Kishino, H.; Yano, T. aki Dating of the human-ape splitting by a
488 molecular clock of mitochondrial DNA. *J. Mol. Evol.* **1985**, *22*, 160–174,
489 doi:10.1007/BF02101694.
- 490 43. Griffiths, R.C.; Tavaré, S. Sampling theory for neutral alleles in a varying environment.
491 *Philos. Trans. R. Soc. Lond. B. Biol. Sci.* **1994**, *344*, 403–410,
492 doi:10.1098/rstb.1994.0079.
- 493 44. Rambaut, A.; Drummond, A.J.; Xie, D.; Baele, G.; Suchard, M.A. Posterior
494 summarization in Bayesian phylogenetics using Tracer 1.7. *Syst. Biol.* **2018**, *67*, 901–904,
495 doi:10.1093/sysbio/syy032.
- 496 45. Oster, A.M.; France, A.M.; Panneer, N.; Cheryl Bañez Ocfemia, M.; Campbell, E.;
497 Dasgupta, S.; Switzer, W.M.; Wertheim, J.O.; Hernandez, A.L. Identifying clusters of
498 recent and rapid HIV transmission through analysis of molecular surveillance data. In
499 Proceedings of the Journal of Acquired Immune Deficiency Syndromes; Lippincott
500 Williams and Wilkins, 2018; Vol. 79, pp. 543–550.
- 501 46. Rich, S.N.; Richards, V.L.; Mavian, C.N.; Switzer, W.M.; Magalis, B.R.; Poschman, K.;
502 Geary, S.; Broadway, S.E.; Bennett, S.B.; Blanton, J.; et al. Employing molecular
503 phylodynamic methods to identify and forecast HIV transmission clusters in public health
504 settings: A qualitative study. *Viruses* **2020**, *12*, 921, doi:10.3390/v12090921.
- 505 47. N.a. Documenting Florida’s path to recovery from the coronavirus (COVID-19)
506 pandemic, 2020-2021 Available online:
507 [https://ballotpedia.org/Documenting_Florida%27s_path_to_recovery_from_the_coronavir](https://ballotpedia.org/Documenting_Florida%27s_path_to_recovery_from_the_coronavirus_(COVID-19)_pandemic,_2020-2021)
508 [us_\(COVID-19\)_pandemic,_2020-2021](https://ballotpedia.org/Documenting_Florida%27s_path_to_recovery_from_the_coronavirus_(COVID-19)_pandemic,_2020-2021).
- 509 48. Response, F.C.-19 Latest Vaccine Updates - Florida Department of Health COVID-19
510 Outbreak Available online: <https://floridahealthcovid19.gov/latest-vaccine-updates/>

- 511 (accessed on Jan 18, 2022).
- 512 49. Mavian, C.; Marini, S.; Prospero, M.; Salemi, M. A snapshot of SARS-CoV-2 genome
513 availability up to 30th march, 2020 and its implications. *bioRxiv* **2020**,
514 2020.04.01.020594, doi:10.1101/2020.04.01.020594.
- 515 50. Mavian, C.; Marini, S.; Manes, C.; Capua, I.; Prospero, M.; Salemi, M. Regaining
516 perspective on SARS-CoV-2 molecular tracing and its implications. *medRxiv* **2020**,
517 2020.03.16.20034470, doi:10.1101/2020.03.16.20034470.
- 518 51. Xavier, J.; Giovanetti, M.; Adelino, T.; Fonseca, V.; Barbosa da Costa, A.V.; Ribeiro,
519 A.A.; Felicio, K.N.; Duarte, C.G.; Ferreira Silva, M.V.; Salgado, Á.; et al. The ongoing
520 COVID-19 epidemic in Minas Gerais, Brazil: insights from epidemiological data and
521 SARS-CoV-2 whole genome sequencing. *Emerg. Microbes Infect.* **2020**, *9*, 1824–1834,
522 doi:10.1080/22221751.2020.1803146.
- 523 52. Rambaut, A. Phylodynamic Analysis | 176 genomes | 6 Mar 2020 - Novel 2019
524 coronavirus / nCoV-2019 Genomic Epidemiology - Virological Available online:
525 <https://virological.org/t/phylodynamic-analysis-176-genomes-6-mar-2020/356> (accessed
526 on Dec 22, 2021).
- 527 53. Mathieu, E.; Ritchie, H.; Ortiz-Ospina, E.; Roser, M.; Hasell, J.; Appel, C.; Giattino, C.;
528 Rodés-Guirao, L. A global database of COVID-19 vaccinations. *Nat. Hum. Behav.* **2021**,
529 *5*, 947–953, doi:10.1038/s41562-021-01122-8.
- 530 54. Alpert, T.; Lasek-Nesselquist, E.; Brito, A.F.; Valesano, A.L.; ... Early introductions and
531 community transmission of SARS-CoV-2 variant B. 1.1. 7 in the United States. *medRxiv*
532 2021, *184*, 2595–2604.
- 533 55. Washington, N.L.; Gangavarapu, K.; Zeller, M.; Bolze, A.; Cirulli, E.T.; Schiabor Barrett,
534 K.M.; Larsen, B.B.; Anderson, C.; White, S.; Cassens, T.; et al. Emergence and rapid
535 transmission of SARS-CoV-2 B.1.1.7 in the United States. *Cell* **2021**, *184*, 2587-2594.e7.
- 536 56. Viana, R.; Moyo, S.; Amoako, D.G.; Tegally, H.; Scheepers, C.; Althaus, C.L.; Anyaneji,
537 U.J.; Bester, P.A.; Boni, M.F.; Chand, M.; et al. Rapid epidemic expansion of the SARS-
538 CoV-2 Omicron variant in southern Africa. *Nature* **2022**, doi:10.1038/d41586-021-03832-
539 5.
- 540